Bringing UC Clinical Decision-Making into Focus for 2020

Faculty

David T. Rubin, MD, FACG, AGAF, FACP, FASGE, FRCP
Joseph B. Kirsner Professor of Medicine
Chief, Section of Gastroenterology, Hepatology and Nutrition
Director, Inflammatory Bowel Disease Center
University of Chicago Medicine
Chicago, IL
David T. Rubin, MD, FACG, AGAF, FACP, FASGE, FRCP

David T. Rubin, MD, FACG, AGAF, FACP, FASGE, FRCP (Edinburgh) is the Joseph B. Kirsner Professor of Medicine, a Professor of Pathology, Chief of the Section of Gastroenterology, Hepatology and Nutrition, and Director of the Inflammatory Bowel Disease (IBD) Center at the University of Chicago Medicine in Chicago, Illinois. Dr. Rubin earned a medical degree with honors at the University of Chicago Pritzker School of Medicine in Chicago, Illinois and completed his residency in internal medicine and fellowships in gastroenterology and clinical medical ethics at the University of Chicago in Chicago, Illinois, where he served as Chief Resident and Chief Fellow. He also serves as Associate Faculty at the MacLean Center for Clinical Medical Ethics, Associate Investigator at the University of Chicago Comprehensive Cancer Center, and is a member of the University of Chicago Committee on Clinical Pharmacology and Pharmacogenomics. He is the chair of the National Scientific Advisory Committee of the Crohn’s & Colitis Foundation, where he also serves as a Board of Trustees member. Dr. Rubin is the deputy chair of the Executive Committee of the International Organization for the Study of Inflammatory Bowel Disease. Prior to these appointments, he served as the Director of the Fellowship in Gastroenterology, Hepatology and Nutrition at the University of Chicago for 11 years. In 2018, Dr. Rubin completed the Harvard T.H. Chan School of Public Health Leadership Development Course for Physicians.

Dr. Rubin is a Fellow of the American Gastroenterological Association (AGA), the American College of Gastroenterology (ACG), the American Society for Gastrointestinal Endoscopy (ASGE), the American College of Physicians (ACP), and the Royal College of Physicians (Edinburgh). He is on the Board of Trustees for the ACG. Among numerous awards and honors, Dr. Rubin was chosen by his peers as a member of Best Doctors (recognized for superior clinical ability) and America’s Top Physicians (gastroenterology). Additionally, he twice received the ACG’s Governor’s Award of Excellence in Clinical Research (2003 and 2013), and the UChicago Postgraduate Teaching Award in recognition of significant contributions for fellowship education (2006). In 2012, he received the Crohn’s & Colitis Foundation’s Rosenthal Award, a national leadership award bestowed upon a volunteer who has contributed in an indisputable way to the quality of life of patients and families. He has previously served as an Associate Editor of the journal Gastroenterology and Editor-in-Chief of the ACG On-Line Education Universe. In 2020, Dr. Rubin received the Sherman Prize for Excellence in Crohn’s and Colitis.

Dr. Rubin is an editor of a best-selling book Curbside Consultation in IBD, now in its 3rd edition, was an associate editor of the 11th edition and is senior editor of the upcoming 12th edition of Sleisenger and Fordtran’s Gastrointestinal and Liver Disease, and an author or coauthor of over 500 articles on treatment and management of IBD, cancer in IBD and novel paradigms, as well as the first author of the 2019 ACG Guidelines for ulcerative colitis. His current research is in the area of novel approaches to monitoring of IBD (wearables and point of care intestinal ultrasound), prevention of progressive complications from uncontrolled inflammation, and a variety of collaborative and translational studies related to the causes of IBD and its complications. His H index is 74. He is also a featured media contact for issues related to IBD, appearing on satellite radio, television, print media and maintains a popular and verified twitter feed @IBDMD with over 20,000 followers.

Adjoa Anyane-Yeboa, MD, MPH
Instructor of Medicine
Division of Gastroenterology Massachusetts General Hospital
Harvard Medical School Boston, MA
Adjoa Anyane-Yeboa, MD, MPH
Instructor of Medicine

Dr. Adjoa Anyane-Yeboa is currently an Instructor of Medicine in the Division of Gastroenterology at Massachusetts General Hospital and Harvard Medical School. She previously completed her medical degree at the University of Cincinnati College of Medicine, her Internal Medicine Residency at the University of Illinois at Chicago where she also later served as Chief Medical Resident, and her Gastroenterology fellowship at the University of Chicago Medicine where she also served as Chief Gastroenterology Fellow. After her medical training, she went on to complete the Commonwealth Fund Fellowship in Minority Health Policy at Harvard Medical School and simultaneously received her Master’s in Public Health with a focus in health policy at the Harvard TH Chan School of Public Health. Her work is centered around healthy equity, and understanding disparities in gastrointestinal disorders such as inflammatory bowel disease and colorectal cancer, with the goal of advancing care and access for minority patients.

Millie D. Long, MD, MPH
Professor of Medicine
Vice-Chief for Education
Director, Gastroenterology and Hepatology Fellowship Program
Division of Gastroenterology and Hepatology
University of North Carolina 
Chapel Hill, NC 
Millie D. Long, MD, MPH

Millie D. Long, MD, MPH, is board certified in internal medicine, preventive medicine, and gastroenterology. Dr. Long received her medical degree from University of Virginia in 2002. She then completed residency in internal medicine and a chief residency at University of Alabama at Birmingham. She completed fellowships in gastroenterology and hepatology, preventive medicine, and inflammatory bowel disease, all at University of North Carolina. She is currently Professor of Medicine in the Department of Medicine and Director of the Gastroenterology and Hepatology Fellowship Program at University of North Carolina at Chapel Hill.

Dr. Long’s clinical practice is at the UNC Multidisciplinary Inflammatory Bowel Diseases (IBD) Center. Her research interests include prevention of complications of IBD, women’s health, and clinical epidemiology. Dr. Long has contributed to over 200 peer-reviewed publications, book chapters, and review articles and to the medical literature. She is the current co-Editor in Chief of the American Journal of Gastroenterology. She also serves as an invited reviewer for journals such as Inflammatory Bowel Diseases and Gastroenterology.

Dr. Long is a fellow of the American College of Gastroenterology, where she serves on the Board of Trustees. She is also a fellow of the American Gastroenterological Association and the Crohn’s and Colitis Foundation, where she co-chairs the Clinical Research Alliance.

Statement of Need

The management of ulcerative colitis (UC) is evolving. In the last 2 years, the American Gastroenterological Association (AGA) and the American College of Gastroenterology (ACG) released updated, evidence-based treatment guidelines with recommendations for disease stratification, prognosis, treatment options, and disease monitoring. Additionally, new efficacy, safety, and comparative effectiveness data from advanced treatment options are now available, and the list is expected to grow with the approval of additional therapies in the future.

In this CME Outfitters webcast, expert faculty will compare the new AGA and ACG guideline recommendations and discuss recent clinical trial and real-world data in order to provide learners with recommendations on selecting the appropriate therapy for individual patients. In addition, faculty will discuss proven strategies to empower, educate, and engage patients in their UC care.

Learning Objectives

At the end of this CME/CE activity, participants should be able to:

  • Compare new AGA and ACG guideline recommendations on the treatment of UC in order to identify the appropriate course of action for individual patients.
  • Differentiate targeted therapies for UC using efficacy, safety, and comparative effectiveness data from clinical trials and real-world experience.
  • Empower and educate patients to become an active part of SDM.

The following learning objectives pertain only to those requesting CNE or CPE credit:

  • Compare new AGA and ACG guideline recommendations on the treatment of UC in order to identify the appropriate course of action for individual patients.
  • Differentiate targeted therapies for UC using efficacy, safety, and comparative effectiveness data from clinical trials and real-world experience.
  • Describe ways to empower and educate patients to become an active part of SDM.

Financial Support

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Target Audience

List the types of medical professionals who will benefit from this course.

Credit Information

Physicians (ACCME) 1.0

CME Outfitters, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Note to Nurse Practitioners

Nurse Practitioners can apply for AMA PRA Category 1 Credit through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit  from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

Pharmacists/Pharmacy Tech (ACPE) 1.0

This application-based activity is approved for 1.0 contact hour (0.10 CEUs) of continuing pharmacy credit.

ABIM MOC 1.0

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.


Dr. Rubin reports that he receives grants from AbbVie Inc.; Genentech, Inc./Roche; Janssen Pharmaceuticals, Inc.; Prometheus Laboratories Inc.; Shire; and Takeda Pharmaceuticals U.S.A., Inc. He is a consultant for AbbVie Inc.; AbGenomics; Allergan; Biomica; Boehringer Ingelheim; Bristol-Myers Squibb Company; Celgene Corporation/ Syneos Health; Check-Cap; Dizal Pharmaceutical; Eli Lilly and Company; GalenPharma/Atlantica; Genentech, Inc./Roche; Gilead Sciences, Inc.; GlaxoSmithKline; Ichnos Sciences SA; InDex Pharmaceuticals; Janssen Pharmaceuticals, Inc.; Narrow River Management; Pfizer Inc.; Prometheus Laboratories Inc.; Reistone Biopharma; Shire; Takeda Pharmaceuticals U.S.A., Inc.; and Techlab, Inc. He is a stock shareholder (directly purchased) in AbGenomics and Biomica. He receives other financial or material support as Co-Founder and CFO of Cornerstones Health, Inc.; and Co-Founder of GoDuRn, LLC. (non-profit).


Dr. Anyane-Yeboa reports she serves on the advisory committee for Pfizer Inc. She is a consultant for SidekickHealth.


Dr. Long reports that she receives grants and research support from Pfizer Inc. and Takeda Pharmaceuticals U.S.A., Inc. She is a consultant for AbbVie Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Prometheus; Takeda Pharmaceuticals U.S.A., Inc.; TARGET PharmaSolutions, Inc.; and UCB, Inc.


Howard Bliwise, MD (peer reviewer) has no disclosures to report.

Mae Ochoa, RPh (peer reviewer) has no disclosures to report.

Olga Askinazi, PhD (planning committee) has no disclosures to report.

Susan Perry (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.


Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Additional Formats

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.

 


NOTE: Pharmacist CE Universal Activity Number, Enduring: 0376-0000-20-127-H01-P

 

Questions about this activity?

Call us at (877) CME-PROS or (877) 263-7767.

 

 


MMV-106-103020-20

Bringing UC Clinical Decision-Making into Focus for 2020
Event Date: 10/30/2020 at 8:00 am EST